Safety of MB-CART2019.1 in Lymphoma Patients (MB-CART2019.1 Lymphoma / DALY 1)

Summary

This is a prospective, multi-center, open phase I/II trial to evaluate feasibility, dosage, safety and toxicity as well as efficacy of ex vivo expanded autologous T cells genetically modified to express anti-CD20 and CD19 immunoreceptor (MBCART2019.1) in patients with relapsed or resistant aggressive CD20 and CD19 positive B-NHL/CLL/SLL.

Timeline

Start

2019-02-25

Primary completion

2020-12-17

Completion

2024-05-28

Publications

• Balke-Want H, Godel P, Schmid C, Ayuk F, Friedrichs B, van Heteren P, Holtkamp S, Zadoyan G, Brillant C, Costa J, Hanssens L, Holzer T, Wohle C, Biedermann S, Burger I, Orentas R, Overstijns T, Scheid C, Holtick U, Miltenyi S, Hallek M, Borchmann P, Kutsch N. Zamtocabtagene autoleucel in relapsed/refractory B-NHL: 5-year follow-up of a CD20/19 tandem CAR T-cell phase 1 trial. Blood Adv. 2026 Apr 14;10(7):2395-2405. doi: 10.1182/bloodadvances.2025018073.

Drugs

Indications